Skip to main content

Table 4 ART choices in the setting of common co-prescriptions

From: HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme

Patients who purchased medication for specified class of co-prescriptiona N =1973b n (%)
Dyslipidemia (any lipid-lowering medication) 385 (19.5)
 Purchased protease inhibitorsc 112 (29.1)
  darunavir 71 (63.4)
  atazanavir 36 (32.1)
  r/lopinavir 9 (8.0)
  fosamprenavir 1 (0.8)
 Purchased efavirenz 60 (15.6)
 Purchased elvitegravir 42 (10.9)
 Purchased abacavir 135 (35.1)
Hypertension or hyperlipidemia or diabetes (at risk for cardiovascular disease) 574 (29.1)
Purchased any protease inhibitorc 155 (27.0)
  darunavir 93 (60.0)
  atazanavir 50 (32.3)
  r/lopinavir 12 (7.7)
  fosamprenavir 2 (1.3)
 Purchased elvitegravir 74 (12.9)
 Purchased abacavir 197 (34.3)
Hypertension or diabetes (at risk for renal disease) 413 (20.9)
 Purchased TDF 230 (55.7)
Osteoporosis or low bone mineral density 27 (1.4)
 Purchased tenofovir disoproxil fumarate 13 (48.1)
Mental illness 525 (26.6%)
 Purchased rilpivirine 79 (15.0)
 Purchased efavirenz 38 (7.2)
Diabetes 91 (4.6)
 Purchased protease inhibitorsc 33 (36.2)
 Purchased ritonavir-containing regimens 24 (26.3)
Proton pump inhibitors 281 (14.2)
 Purchased rilpivirine 15 (5.3)
 Purchased atazanavir 11 (3.9)
Oral contraceptives 12 (0.6)
 Purchased protease inhibitorsc 4 (33.3)
 Purchased efavirenz 3 (25.0)
 Purchased elvitegravir 1 (8.3)
Corticosteroids (oral and inhaled except beclomethasone) 179 (9.1)
 Purchased protease inhibitorsc 46 (25.7)
  1. aCo-prescriptions purchased within a month before or after the antiretroviral purchase were analysed
  2. bTwenty-two patients of the 1995 patients that purchased ART in 2016 died during 2016 and were excluded from this analysis
  3. cboosted with ritonavir or cobicistat or unboosted